Paul A. DiSilvestro, MD, director, Gynecologic Oncology, the Program in Women’s Oncology, , New England Health System, division director, Gynecologic Oncology, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, discusses the long-term survival benefit of olaparib (Lynparza) maintenance in advanced 

At the 2022 ESMO Congress, investigators presented a 7-year overall survival (OS) analysis of the phase 3 SOLO-1 trial (NCT01844986), which examined olaparib monotherapy vs placebo as maintenance for patients with 

-mutated ovarian cancer following a response to first-line chemotherapy.

Patients who achieved a complete or partial response to first-line platinum-based chemotherapy were randomly assigned to olaparib maintenance or placebo, with treatment continuing for up to 2 years or until disease progression, DiSilvestro says. Although the primary end point of the trial was progression-free survival, and OS was a key secondary end point, DiSilvestro explains.

Although 7 years of follow-up have been conducted on SOLO-1, OS events have occurred in only 32.3% of patients in the olaparib arm, DiSilvestro continues. The 84-month OS rate in the olaparib arm was 67%, compared with 46.5% in the placebo arm. With a prespecified OS analysis planned to be conducted when OS data are 60% mature, investigators will need to wait a few more years to find the true OS benefit of olaparib; however, the OS benefit observed so far has been excellent for patients, DiSilvestro concludes.

Videos

Paul A. DiSilvestro, MD, discusses the long-term survival benefit of olaparib maintenance in advanced BRCA-mutated ovarian cancer.


Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian Cancer

Paul A. DiSilvestro, MD, director, the Program in Women’s Oncology, Women & Infants Hospital of Rhode Island and Care New England Health System, division director, Gynecologic Oncology, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, discusses the 7-year follow up data of maintenance olaparib (Lynparza) in advanced ovarian cancer.

The phase 3 SOLO-1 trial (NCT01844986) examines maintenance olaparib monotherapy vs placebo in patients with 

-mutated ovarian cancer following first-line chemotherapy.

In this descriptive analysis, investigators analyzed the data with a very low alpha spend which is why the overall survival (OS) results were clinically meaningful, but not statistically significant, DiSilvestro says. The median OS in the maintenance olaparib arm has yet to be reached, and the median overall survival in the placebo arm is 75 months, DiSilvestro explains. This yields a hazard ratio of 0.55 or a 45% reduction in the risk of death for patients 7 years after their diagnosis, DiSilvestro adds.

This means, 67% of women in the olaparib arm were alive 7 years after their diagnosis vs 47% in the placebo arm, DiSilvestro concludes. 

Paul A. DiSilvestro, MD, discusses the 7-year follow up data of maintenance olaparib in advanced ovarian cancer.

Paul A. DiSilvestro, MD

Articles

Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian Cancer

Dr. DiSilvestro on 7-Year Follow up of Olaparib Maintenance in Advanced Ovarian Cancer